プロモーションスケジュール OncoCyte Corporation
詳細なスケジュール
簡易グラフ
会社について OncoCyte Corporation
OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. さらに詳しく| IPO date | 2016-01-04 |
|---|---|
| ISIN | US68235C1071 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://oncocyte.com |
| Цена ао | 3.87 |
| 1日あたりの価格変動: | -3.36% (3.87) |
|---|---|
| 週ごとの価格変動: | -4.1% (3.9) |
| 月ごとの料金変更: | +49% (2.51) |
| 3ヶ月間の価格変動: | +61.21% (2.32) |
| 半年間の価格変動: | +18.73% (3.15) |
| 年間の価格変動: | +25.5% (2.98) |
| 3年間の価格推移: | +167.14% (1.4) |
| 5年間の価格推移: | +49% (2.51) |
| 年初からの価格変動: | +69.23% (2.21) |
|
|
過小評価
|
効率
|
|||||||||||||||||||||||||||||||||||||
配当金
|
義務
|
成長の衝動
|
|||||||||||||||||||||||||||||||||||||
| 機関 | 音量 | 共有, % |
|---|---|---|
| Broadwood Capital, Inc. | 2509066 | 30.37 |
| AWM Investment Company, Inc. | 754286 | 9.13 |
| PURA VIDA INVESTMENTS, LLC | 586930 | 7.11 |
| Vanguard Group Inc | 247873 | 3 |
| Morgan Stanley | 122973 | 1.49 |
| Defender Capital, LLC | 71650 | 0.87 |
| Geode Capital Management, LLC | 61482 | 0.74 |
| Blackrock Inc. | 60187 | 0.73 |
| State Street Corporation | 16289 | 0.2 |
| Renaissance Technologies, LLC | 12718 | 0.15 |
| ETF | 共有, % | 年間の利益率, % | 配当金, % |
|---|---|---|---|
| iShares Micro-Cap ETF | 0.00668 | 17.09 | 1.54048 |
| 0.01 | 17.09 | 1.54 |
| スーパーバイザー | 役職 | 支払い | 生年 |
|---|---|---|---|
| Mr. Joshua Riggs | President, CEO & Director | 504.63k | 1983 (42 年) |
| Mr. James Liu | Senior Director, Controller & Principal Accounting Officer | 259.83k | 1996 (29 年) |
| Dr. Ekkehard Schutz M.D., Ph.D. | Chief Science Officer | 409.27k | |
| Mr. Yuh-Min Chiang Ph.D. | Chief Technology Officer | N/A | |
| Dr. Michael D. West Ph.D. | Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc. | N/A | 1953 (72 年) |
| Mr. Peter Hong | VP, General Counsel & Secretary | N/A | |
| Ms. Andrea Susan James | Chief Financial Officer | ||
| Ms. Sandra O'Donald | Senior Vice President of Business Operations |
